LIFE aTyr Pharma, Inc.

3.50
+0  (1%)
Previous Close 3.45
Open 3.50
Price To book 1.30
Market Cap 83.12M
Shares 23,748,000
Volume 34,437
Short Ratio 2.27
Av. Daily Volume 230,213

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 1H 2017.
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Data from first four patients released December 13, 2016.
Resolaris
Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B

Latest News

  1. ATYR PHARMA INC Financials
  2. Atyr Pharma reports 4Q loss
  3. Atyr Pharma reports 4Q loss
  4. ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  5. aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases
  6. aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  7. aTyr Pharma Rises 16% on Orphan Drug Status
  8. aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference
  9. aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
  10. High court ruling limits international reach of patent laws
  11. High court ruling limits international reach of patent laws
  12. Atyr Pharma Stock Spikes 33% on FDA Updates
  13. FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
  14. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure
  15. Roberts recuses from patent case after discovering conflict
  16. Roberts recuses from patent case after discovering conflict
  17. Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
  18. Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers?
  19. aTyr Pharma Drops on Clinical Update
  20. ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events